Background: Renin-dependent hypertension with tubulointerstitial injury remains a problem with high prevalence in the clinic. However, whether and how renin participates in tubulointerstitial injury remains incompletely understood. New evidence suggests that renin cleaves C3 into C3a and C3b. In the present study, we aimed to explore the role of renin-mediated C3a/C3a receptor (C3aR) signaling in renin-dependent hypertension-induced kidney injury and illustrate the detailed mechanisms. Methods: C3a concentration changes in serum from healthy volunteers incubated with recombinant renin were detected by ELISA. C3aR expression in human tubular epithelial cells was evaluated in renal biopsy sections from malignant arteriolonephrosclerosis and benign arteriolonephrosclerosis patients. C3aR changes in human kidney 2 (HK2) cells were detected after the cells were treated with human serum, renin, and aliskiren. The C3a analogue and C3aR antagonist SB290157 were used to stimulate HK2 cells to explore the downstream signaling of C3a/C3aR activation. For in vivo studies, two-kidney, one-clipped (2K1C) hypertensive rat model was established to simulate renin-dependent hypertension conditions. C3a and C3aR expression was detected in the clipped kidneys. SB290157 was injected intraperitoneally to block C3a/C3aR signaling in 2K1C rats. Results: The results showed that renin cleaved C3 into C3a and activated C3aR signaling in tubular epithelial cells (TECs) from both humans and rats. In vitro results demonstrated that C3a/C3aR activation impaired peroxisome proliferator-activated receptor alpha (PPARα)/carnitine palmitoyltransferase-1alpha (CPT-1α)-mediated mitochondrial fatty acid oxidation (Mito FAO) in HK2 cells and induced HK2 cell transition to a profibrotic phenotype, which was inhibited by treatment with the C3aR antagonist SB290157. In vivo results showed that renin mRNA levels, C3a concentrations, C3aR levels and tubulointerstitial fibrosis increased concurrently in the clipped kidney cortex of 2K1C rats. Treatment with the C3aR antagonist SB290157 significantly mitigated the effect of renin induction of C3aR expression and alleviated renin-dependent hypertension-induced tubulointerstitial fibrosis by improving PPARα/CPT-1α-mediated Mito FAO in TECs, as well as inhibiting tubulointerstitial fibrosis transition. Conclusions: Our results prove that renin activates C3a/C3aR signaling to promote renal tubulointerstitial fibrosis by impairing PPARα/CPT-1α-mediated tubular Mito FAO. SB290157 confers a potential therapeutic approach for renin-dependent hypertension-induced kidney injury.

Keywords: hypertension-induced kidney injury; renin; C3a; C3a receptor; mitochondrial fatty acid oxidation; profibrotic phenotype transition

1. Introduction

Hypertension is one of the most common causes of secondary kidney diseases and a major contributor to chronic renal dysfunction [1, 2]. Overactivation of the sympathetic nervous system [3] or renal artery stenosis [4] leads to low renal blood flow and subsequently increased renin secretion from the juxtaglomerular apparatus, which result in renin-dependent hypertension. Recently, a curious relationship among the renin-angiotensin system (RAS), immune activation and tubular injury is highlighted [5]. New evidence suggests that renin can cleave C3 to produce C3a and C3b, and the application of renin inhibitors reduces renin-induced C3 cleavage and mitigates tubulointerstitial injury [6, 7]. However, the mechanisms by which renin affects tubulointerstitial injury are not fully understood.

Complement C3, as the central molecule of the complement system, has been implicated in the pathogenesis of several chronic kidney diseases (CKDs) [8–10]. Reportedly, C3 and its cleavage fragments accumulate in the glomerular capillaries and arterioles of the kidneys in patients with hypertension [11]. The intensity of C3 deposition is associated with the severity of hypertension-induced kidney injury [12, 13]. Apart from serum-derived C3 deposition, local synthesis of C3 under disease conditions also contributes to renal damage [14]. C3a, the smaller cleavage fragment of C3, can regulate intracellular signaling by binding to the C3a receptor (C3aR), which is located on the cellular membrane [15]. In the kidney cortex, C3aR is mainly expressed in tubular epithelial cells (TECs) and interstitial infiltrating immune cells such as...
monocytes and macrophages [16,17]. Evidence has revealed that C3α/C3αR signaling plays a vital role in renal tubulointerstitial fibrosis in several CKD models, such as unilateral ureteral obstruction model and adriamycin-induced proteinuria model, by promoting tubular profibrotic phenotype transition and mesenchymal transition [18–20]. In addition, C3α inhibition has been reported to be a promising treatment to alleviate tissue fibrosis in different disease models [21,22]. However, the effect of renin-induced C3α/C3αR signaling on the renal tubulointerstitium and the effect of C3αR antagonist on renin-dependent hypertension-induced kidney injury have not been fully elucidated. Studies suggest that hypertension suppresses peroxisome proliferator-activated receptor alpha (PPARα)-mediated lipid metabolism in TECs, resulting in abnormal lipid accumulation and aggravating the development of hypertension-induced tubulointerstitial injury [23]. The activation of C3α/C3αR signaling has been reported to modulate lipid metabolism in different types of cells [24,25]. Nevertheless, whether renin/C3α/C3αR signaling promotes hypertension-induced kidney injury by impairing PPARα-mediated lipid metabolism remains unknown.

Here, we conducted in vitro and in vivo experiments to simulate the renin-dependent hypertension suppresses kidney injury microenvironment to explore how renin/C3α/C3αR signaling regulates renal tubulointerstitial injury and illustrates whether the C3αR antagonist SB290157 can protect against renin-dependent hypertension-induced kidney injury by restoring mitochondrial fatty acid oxidation (Mito FAO) and mitigating mesenchymal transition through C3α/C3αR signaling.

2. Materials and Methods

2.1 Incubation of Volunteer Serum with Recombinant Human Renin

Serum samples collected from seven healthy volunteers were stored in aliquots at −80 °C. After a 1:10 dilution in Dulbecco’s phosphate-buffered saline (DPBS, Gibco, Waltham, MA, USA), serum samples were incubated with recombinant renin (1.2 µg/mL, BioVision, Waltham, MA, USA) or phosphate-buffered saline (PBS, Gibco) at 37 °C for 24 h. After incubation, the C3α level of the samples was detected immediately with a Complement C3a Human ELISA Kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.

2.2 HK2 Cells Culture and Stimulation

Immortalized human tubular epithelial cells (human kidney 2 (HK2) cells, CRL-2190, ATCC, Manassas, VA, USA) were routinely cultured in Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 (DMEM/F12, Gibco) containing 10% fetal bovine serum (FBS, Gibco) as described previously [26]. The cell lines were mycoplasma-free (Mycoplasma Detection Kit, Yeasen, Shanghai, China) and authenticated by STR identification.

HK2 cells were treated with 10% serum from healthy volunteer 7 (H7) supplemented with recombinant renin (1.2 µg/mL) or PBS at 37 °C for 24 h. Aliskiren (10 µM, MedChemExpress, Monmouth Junction, NJ, USA), a specific renin inhibitor, was preincubated with recombinant renin for 1 h before addition.

A C3α analogue, which has been reported to mimic the natural biological activity of C3α [27,28], was used to explore the effect of C3α/C3αR activation. HK2 cells were treated with the C3α analogue (1 µg/mL, Sangon Biotech, Shanghai, China) or PBS for 24 h. For C3αR inhibition, cells were pretreated with the C3αR antagonist SB290157 (1 µM, Sigma–Aldrich, St. Louis, MO, USA) for 1 h. HK2 cells were harvested for western blotting analysis, and the culture medium was used to evaluate the concentration of transforming growth factor β (TGFβ) using Human TGFβ ELISA kits (Proteintech, Wuhan, China) according to the manufacturer’s instructions.

2.3 Immunocytochemistry (ICC) Staining

HK2 cells after the treatment were fixed in 4% paraformaldehyde and permeabilized in 0.2% Triton X-100, followed by incubation with 2% BSA for 1 h. The cells were then incubated with PPARα antibodies (1:100, Thermo Scientific) at 4 °C overnight and subsequently with the Alexa Fluor® 488-conjugated secondary antibody (1:500, Abcam, Discovery Drive, Cambridge, UK) at 37 °C for 45 min. DAPI (1:1000, Sigma–Aldrich) was used to counterstain cellular nuclei. The cells were observed under a fluorescence microscope. The intensity of PPARα fluorescence was quantified using ImageJ (version 1.51, National Institutes of Health, Bethesda, MD, USA).

2.4 Detection of Free Fatty Acid and Mitochondria

The fatty acid uptake probe in the Fatty Acid Uptake Assay Kit (Dojindo Laboratories, Kamimashiki-gun, Kumamoto, Japan) functions as a fatty acid analogue and shows the cellular uptake capacity of fatty acids directly. MitoBright LT Deep Red (Dojindo Laboratories) can mark the mitochondria. HK2 cells completing the treatment were stained with the fatty acid probe and subsequently with MitoBright LT Deep Red. The cells were observed by confocal microscopy (LSCM, LSM800, Zeiss, Oberkochen, Germany). The colocalization between the fatty acid probe and MitoBright LT Deep Red was measured by ImageJ with the Coloc 2 plugin and presented as Manders’ coefficients.

2.5 Human Kidney Samples

Three patients with malignant arterionephrosclerosis (MANS) and three patients with benign arterionephrosclerosis (BANS) were included in this study. The study protocol was approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. All of the kidney tissues were obtained from renal biopsies. Informed consent was obtained from all of the patients. Paraffin-embedded kidney sections were prepared for immunofluorescence.
2.6 Incubation of the Rat C3 Protein with Recombinant Rat Renin

Recombinant rat renin protein (active) (Abcam) and rat C3 protein (Complement Technology, Tyler, TX, USA) were used in the experiment. Purified rat C3 protein (100 µg/mL) was incubated with recombinant rat active renin at concentrations of 0, 1.2, 12.5, and 25 µg/mL at 37 °C for 24 h. After incubation, the sample was mixed with 5× loading buffer (Beyotime, Shanghai, China) and boiled for 10 min. Samples with equal volume were used to conduct western blotting analysis to detect the cleavage fragment of C3.

2.7 Animals and Two-Kidney, One-Clipped (2K1C) Rat Hypertension Model

Male Sprague–Dawley (SD) rats weighing 150–170 g were purchased from Charles River Laboratories (Beijing, China) and housed at optimal temperature (±2 °C) with a 12-hour light-dark cycle. The animal experiments were approved by the Animal Experiments Ethics Committee of Charles River Laboratories. Rats were accustomed to the housing conditions for 3 days prior to the experiments. For the 2K1C model, the rats were anesthetized with isoflurane (induction: 5%, maintenance: 2%), and the left kidney was exposed through a dorsal flank incision. A U-shaped silver clip with a 0.25 mm inner diameter (Alcott Biotech, Shanghai, China) was placed on the left renal artery. The same surgery was performed on the rats in the sham group but without the clip. The animals were sacrificed at 2 or 4 weeks after the surgery to collect plasma, serum and renal cortex tissue for further analysis.

2.8 C3aR Antagonist Treatment

The C3aR antagonist SB290157 was used to inhibit C3a/C3AR signaling activation in vivo. SB290157 was intraperitoneally injected into rats at a dose of 3 mg/kg per day for 4 weeks after the surgery. The nondrug-treated groups received an equal volume of vehicle at the same time.

2.9 Blood Pressure Measurement

The tail artery blood pressure of rats was measured at different time points (before the surgery and 2 weeks and 4 weeks after the surgery) using the BP-2000 Blood Pressure Analysis System (Visitec Systems, Apex, NC, USA). Prior to the measurement, all rats were acclimated in restraints. The blood pressure of each rat was determined by averaging 3 records.

2.10 Analysis of Plasma Renin, Plasma C3a and Kidney Tissue C3a Levels

Plasma samples were collected from rats using EDTA-coated Eppendorf tubes. The concentration of renin in plasma was measured using a Renin Assay Kit (Fluorometric) (Abcam). For acquiring kidney tissue homogenates, a piece of kidney cortex tissue from each sample was weighed. We added PBS (tissue weight (g): PBS volume (mL) = 1:9) and two beads to each vial containing the sample and homogenized the tissue at 60 Hz for 30 s for three times with Tissue Grinders (Jingxin, Shanghai, China) to obtain tissue homogenates. The homogenates were centrifuged 5000 ×g at 4 °C for 10 min to obtain the supernatant. The concentrations of C3a in plasma and kidney tissue homogenates were measured using a Rat C3a ELISA Kit (Elabscience), according to the manufacturer’s instructions.

2.11 Renal Function and Histology Analysis

The level of serum creatinine (Scr) was determined by using a liquid chromatography-tandem mass spectrometry (LC–MS/MS) method according to the manufacturer’s instructions. The severity of tubular damage was assessed by two nephrologists in a blinded manner after observing whole kidney sections by hematoxylin-eosin (H&E) staining. Tubular damage was scored from 0 to 4 according to the distribution of lesions as follows: 0, no lesions; 1, less than 25%; 2, 25–50%; 3, 50%–75%; and 4, more than 75%. Renal tubulointerstitial fibrosis was quantified as the percentage of blue area per field in Masson’s trichrome-stained sections using ImageJ, and ten fields of view for each sample were used to collect the data.

2.12 Western Blotting Analysis

The renal cortex tissue and cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (Sigma–Aldrich) containing a protease/phosphatase inhibitor cocktail (NCM Biotech, Jiangsu, China). The protein concentration of the samples was measured with a bicinchoninic acid assay (BCA) protein quantitation kit (Beyotime). Equal amounts of protein (20 µg for cells and 30 µg for tissues) were separated via 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane. After incubation in fast blocking buffer (EpiZyme, Shanghai, China), the membrane was incubated with the following primary antibodies at 4 °C overnight: anti-C3aR (1:1000, Bioss, Beijing, China), anti-C3/C3b (1:2000, Abcam), anti-PPARα (1:1000, Proteintech), anti-PPARγ antibodies (1:1000, Thermo Scientific), anti-carnitine palmitoyltransferase-I alpha (CPT-1α, 1:5000, Proteintech), anti-α-smooth muscle actin (α-SMA, 1:4000, Sigma–Aldrich) and anti-GAPDH (1:5000, Proteintech). After 3 washes, the membranes were then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2500, Cell Signaling Technology, Danvers, MA, USA) at room temperature for 1 h. The visualized signal bands were measured using enhanced chemiluminescence (EpiZyme) through a chemiluminescence imaging system (Tanon, Shanghai, China). The intensity of the bands was determined with ImageJ. Target protein levels were normalized to GAPDH and expressed as fold change relative to the control group.
2.13 RNA Extraction, Reverse Transcription, and Quantitative Reverse Transcription PCR (RT–qPCR)

Total RNA from renal cortex tissues and cells was extracted using the FastPure Cell/Tissue Total RNA Isolation Kit (Vazyme, Jiangsu, China). Complementary DNA was generated using the HiScript® III 1st Strand cDNA Synthesis Kit (+gDNA wiper) (Vazyme), and qPCR was performed using the ChamQ Universal SYBR qPCR Master Mix (Vazyme). The specific primers used were as follows: Rat REN (F) GATCACCATGAAGGGGTCTCTGT (R) GTTCTGGAAGGGATTTCCTTGCC; Rat C3aR (F) AGGCAATGGGCTGGTGCTGT (R) CAGGAGACACTGGCAAC; Rat α-SMA (F) AC-CATCGGGAATGAACGCTT (R) CTGTCAGCAAT-GCCTGGGT; Rat TGFβ (F) ATACGCCGTAGTG-GCTGTCT (R) TGGGACTGATCCCATTGATT; Rat CD68 (F) TGTTCACTCTCAAGGCCAAA (R) GCTCT-GATGTGCGTCTCTGTT; and Rat GAPDH (F) GCTTCCCGTGTTCCTA (R) AGACACCTGATGCTCTCA. Data were expressed as an amplification number based on $2^{-\Delta\Delta Ct}$ normalized to GAPDH and compared with controls.

2.14 Transmission Electron Microscopy (TEM)

The renal cortex tissues were cut into 1 mm³ sections and fixed in 2.5% glutaraldehyde. The tissues were then fixed in 1% osmium tetroxide, dehydrated in a graded ethanol series, embedded in hard resin and sectioned into ultrathin slices (80 nm) using an ultramicrotome (Leica, Wetzlar, Germany). The slices were then stained with uranyl acetate and lead citrate before being observed. We focused on observing lipid droplets in tubular epithelial cells.

2.15 Immunofluorescence

The kidneys were fixed in 4% paraformaldehyde, embedded in paraffin and cut into 4-μm-thick sections. After dehydration and antigen retrieval by EDTA (pH 9.0) under high temperature and high pressure, the kidney sections were then incubated with the following primary antibodies at 4 °C overnight: anti-E-cadherin (E-cad) antibody (1:4000, TSA, Proteintech), anti-C3aR antibody (1:100, Bioss), anti-CD68 antibody (1:200, Servicebio, Wuhan, China), anti-α-SMA antibody (1:200, Sigma–Aldrich), anti-PPARα antibodies (1:100, Thermo Scientific) and anti-aquaporin 1 (AQP1) antibodies (1:200, Abcam). The kidney sections were then incubated with secondary antibodies at 37 °C for 45 min. For TSA staining, the sections were additionally incubated with FITC-tyramide solution protected from light for 10 min. DAPI was used to counterstain cell nuclei. The kidney sections were observed under a fluorescence microscope. The fluorescence intensity of C3aR, PPARα and the CD68% positive area of each sample were determined by ImageJ. Five fields of view of each sample from patients and ten fields of view from each sample from rats were used for analysis. Fields of view at 200× magnification were located in the renal cortex and chosen randomly under the microscopy. After acquiring the images of the specific channel, the images were converted to an 8-bit image and the positive area was included by setting a certain threshold. After selecting “Limit to Threshold” option in the “Set Measurements”, the mean fluorescence intensity and the percentage of positive area could be quantified using ImageJ [29]. The fluorescence intensity of each sample was determined by averaging the data from five or ten images. The mean intensity of the control group in each experiment was used as a reference in the statistical analysis.

The colocalization of PPARα and nuclei was measured by ImageJ with the Coloc 2 plugin and presented as Manders’ coefficients.

2.16 Statistical Analysis

The distribution of data were examined by Shapiro-Wilk test. The values for each parameter were expressed as the mean ± SEM. Statistical analysis were performed using GraphPad 8.0 (GraphPad Software, La Jolla, CA, USA). Two-tailed, unpaired Student’s $t$ tests were used when comparing two groups. One-way ANOVA followed by Tukey’s multiple comparisons test was used to compare the differences between groups when there were more than two groups. Paired $t$ tests were performed to analyze the differences between the serum-recombinant human renin incubation groups and the serum-PBS incubation groups. $p < 0.05$ was considered statistically significant.

3. Results

3.1 Recombinant Human Renin Increases the C3a Concentration in Human Serum

Serum from seven healthy volunteers was collected and incubated with recombinant human renin or PBS. As shown in Table 1, the C3a concentration in serum incubated with recombinant renin increased significantly compared to that in the same samples incubated with PBS (with renin 922.16 ± 312.90 ng/mL vs. with PBS 561.52 ± 156.54 ng/mL, $t = 2.989$, $p = 0.024$). The median level of C3a (C3a concentration with renin-C3a concentration with PBS) in these samples was 198.56 (134.46, 810.24) ng/mL.

3.2 Renin Induces C3a/C3aR Activation in Human Tubular Epithelial Cells

As C3aR is mainly expressed in TECs, we used serum from H7 incubated with human recombinant renin to stimulate HK2 cells and investigated the change in C3aR. As shown in Fig. 1A, treatment with serum incubated with recombinant renin significantly increased the protein level of C3aR in HK2 cells. The addition of aliskiren, a renin inhibitor, reversed the change in C3aR protein levels.

To further validate the results in human kidneys, we performed immunofluorescence staining of C3aR in kidney samples from 6 hypertensive patients who underwent renal biopsy. Among them, 3 were diagnosed with BANS
Table 1. Comparison of C3a concentrations in serum samples from 7 healthy volunteers after incubation with recombinant human renin or PBS.

<table>
<thead>
<tr>
<th>Patient</th>
<th>C3a Concentration with PBS (ng/mL)</th>
<th>C3a Concentration with Renin (ng/mL)</th>
<th>ΔC3a Concentration (ng/mL)</th>
<th>t-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>H1</td>
<td>340.78</td>
<td>444.23</td>
<td>103.45</td>
<td>2.989</td>
<td>0.024*</td>
</tr>
<tr>
<td>H2</td>
<td>560.23</td>
<td>758.79</td>
<td>198.56</td>
<td>1.954</td>
<td>0.067</td>
</tr>
<tr>
<td>H3</td>
<td>644.18</td>
<td>778.64</td>
<td>134.46</td>
<td>1.954</td>
<td>0.067</td>
</tr>
<tr>
<td>H4</td>
<td>577.3</td>
<td>851.79</td>
<td>274.49</td>
<td>4.145</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>H5</td>
<td>835.77</td>
<td>1006.8</td>
<td>171.03</td>
<td>2.037</td>
<td>0.054</td>
</tr>
<tr>
<td>H6</td>
<td>534.45</td>
<td>1344.69</td>
<td>810.24</td>
<td>17.98</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>H7</td>
<td>437.96</td>
<td>1270.15</td>
<td>832.19</td>
<td>15.74</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

\( \Delta C3a \) concentration = C3a concentration with renin-C3a concentration with PBS; \( *p < 0.05 \) by paired t test.

Fig. 1. Renin induces C3aR expression in renal tubular epithelial cells. (A) Representative western blotting images and summarized data showing the effect of renin-incubated serum and aliskiren intervention on C3aR protein levels in HK2 cells. N = 3, by one-way ANOVA. (B) Representative immunofluorescence staining images of C3aR and E-cad in kidney sections of recruited patients with MANS and BANS (200×; scale bar, 100 µm; the right panel shows magnified images of the boxed areas in the left panel, arrow, positive staining of C3aR) and summarized relative mean intensity of C3aR fluorescence. MANS, malignant arteriolonephrosclerosis; BANS, benign arteriolonephrosclerosis; N = 3, by independent t test. \( ^{**}p > 0.05 \), \( ^{*}p < 0.05 \), \( ^{**}p < 0.01 \).

and 3 were diagnosed with MANS. Compared to patients with BANS, the patients with MANS were characterized by higher Scr, lower eGFR, higher renin activity and more severe tubulointerstitial fibrosis (Table 2). The results revealed areas with high C3aR expression in tubular epithelial cells (marked by E-cad) in patients with MANS (Fig. 1B). The relative fluorescence intensity of C3aR (Fig. 1B), as well as the plasma renin activity in MANS patients (with MANS 2.49 ± 0.62 ng/mL vs. with BANS 0.36 ± 0.17 ng/mL, \( t = 5.716, p = 0.005 \)), was markedly higher than that in patients with BANS (Table 2). Pearson analysis revealed that the relative fluorescence intensity of C3aR was positively correlated with renin activity levels in these patients (\( r = 0.859, p = 0.029 \), data not shown). These results indicated that human renin could activate C3a/C3aR signaling in human tubular epithelial cells during the progression of hypertension.

3.3 SB290157 Restores PPARα/CPT-1α-Mediated Mito FAO in HK2 Cells by Inhibiting C3a/C3aR Signaling

Although renin can cleave serum C3 into C3a, it can also catalyze angiotensinogen to generate angiotensin II,
which also influences the downstream signaling of C3aR [30]. To avoid the effect of angiotensin II, we used a C3a analogue that has been reported in previous studies in the following experiments.

The C3a analogue also significantly increased the C3aR protein level in HK2 cells (Fig. 2A). Notably, the C3a analogue triggered the synthesis of TGFβ, a classic profibrotic factor, and promoted its secretion (Fig. 2A,B). The C3a analogue reduced the protein levels of PPARα, the key regulator of Mito FAO, as well as that of CPT-1α, the rate-limiting enzyme of Mito FAO in HK2 cells (Fig. 2C). Immunocytochemistry staining results also revealed decreased PPARα expression in HK2 cells upon treatment with the C3a analogue (Fig. 2D). Additionally, the colocalization between the fatty acid probe and Mito tracker was decreased in HK2 cells treated with the C3a analogue, indicating a reduction in the mitochondrial uptake of fatty acids for FAO (Fig. 2E). Pretreatment of HK2 cells with the C3aR antagonist SB290157 blocked the effect induced by the C3a analogue, as indicated by a decrease in C3aR and TGFβ protein levels, an increase in PPARα and CPT-1α protein levels and an increase in mitochondrial uptake of fatty acids (Fig. 2). These results suggested that the activation of C3a/C3aR signaling could inhibit PPARα/CPT-1α-mediated tubular Mito FAO and induce TECs transformation into a profibrotic phenotype, whereas SB290157 attenuated tubular changes by targeting C3aR.

### 3.4 Rat C3 Cleavage by Renin

Renin is a species-specific enzyme. No evidence has shown whether rat renin can cleave C3 in rats. Before performing the validation experiments in vivo, we carried out western blotting analysis to detect the effect of rat renin on rat C3. Interestingly, western blotting analysis showed that the level of C3 cleavage increased as the concentration of renin increased, as indicated by the increasing contents of iC3b and C3c, two C3 cleavage fragments (Fig. 3A). Slight increases in the contents of iC3b and C3c were detected when purified rat C3 protein was incubated with rat recombinant renin at 1.2 µg/mL and 12.5 µg/mL, but not statistically significant. Statistical analysis showed that renin-mediated C3 cleavage reached its highest level with 25 µg/mL renin (Fig. 3B,C). The above results demonstrated that rat renin could cleave C3.

### 3.5 Renin Levels Increase Synchronously with C3a and C3aR Levels in the Clipped Knees of 2K1C Rats

Renin-dependent hypertension 2K1C rat model was used for in vivo experiments. As shown in Fig. 4A, the blood pressure (BP) of 2K1C rats was significantly elevated at 2 weeks (170 ± 7/112 ± 9 mmHg) and progressed to 205 ± 15/137 ± 14 mmHg at 4 weeks after the surgery, while the BP of the sham group remained at approximately 120/50 mmHg during this period. No difference in Scr levels was found in 2K1C rats at 2 weeks compared to that of the sham group; however, at 4 weeks, the Scr levels in 2K1C rats significantly increased compared with those in sham group (Fig. 4B). Based on its higher BP and Scr levels, 4 weeks was chosen as the time point for the following experiments.

As shown in Fig. 4C, the plasma renin concentration of 2K1C rats increased markedly at 4 weeks (2K1C 18.00 ± 5.18 ng/mL vs. sham 9.61 ± 2.06 ng/mL, p < 0.05). However, no difference in plasma C3a levels was found between the two groups (Fig. 4D, 2K1C 336.6 ± 55.3 ng/mL vs. sham 339.9 ± 101.5 ng/mL, p > 0.05). RT–qPCR results showed a marked increase in renin mRNA levels in the clipped kidney tissues but not the nonclipped side of 2K1C rats (Fig. 4E). ELISA experiments also showed a significant increase in C3a levels in clipped kidney tissues but not in nonclipped kidney tissues (Fig. 4F). H&E staining showed that the clipped kidneys of 2K1C rats exhibited extensive tubulointerstitial injury compared with those of the rats in the sham group, with more tubular atrophy and dilation, more cast formation, more extensive inflammatory cell infiltration and higher tubular damage score (Fig. 4G,H). Masson’s trichrome staining showed that the clipped kidneys of 2K1C rats manifested more collagen deposition and fibrosis foci, as evaluated by collagen volume fraction analysis (Fig. 4I,J).

After 4 weeks of 2K1C, the protein levels of C3aR and α-SMA (a marker of myofibroblasts) were markedly

### Table 2. The characteristics and laboratory results of 6 recruited patients that accepted renal biopsy.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Age (year)</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Disease duration</th>
<th>SBP (mmHg)</th>
<th>DBP (mmHg)</th>
<th>Scr (umol/L)</th>
<th>Proteinuria (mg/24 h)</th>
<th>eGFR (mL/min/1.73 m²)</th>
<th>Renin activity (ng/mL/h)</th>
<th>Plasma C3 (g/L)</th>
<th>TIF degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>33</td>
<td>M</td>
<td>BANS</td>
<td>3</td>
<td>145</td>
<td>96</td>
<td>95</td>
<td>256</td>
<td>95.2</td>
<td>0.42</td>
<td>0.93</td>
<td>+</td>
</tr>
<tr>
<td>P2</td>
<td>65</td>
<td>M</td>
<td>BANS</td>
<td>30</td>
<td>143</td>
<td>79</td>
<td>140</td>
<td>1755</td>
<td>46.9</td>
<td>0.50</td>
<td>1.15</td>
<td>+</td>
</tr>
<tr>
<td>P3</td>
<td>29</td>
<td>M</td>
<td>BANS</td>
<td>2</td>
<td>200</td>
<td>110</td>
<td>117</td>
<td>7004</td>
<td>67.9</td>
<td>0.17</td>
<td>1.23</td>
<td>++</td>
</tr>
<tr>
<td>P4</td>
<td>29</td>
<td>M</td>
<td>MANS</td>
<td>2</td>
<td>220</td>
<td>145</td>
<td>259</td>
<td>1145</td>
<td>27.6</td>
<td>2.53</td>
<td>0.73</td>
<td>+++</td>
</tr>
<tr>
<td>P5</td>
<td>30</td>
<td>M</td>
<td>MANS</td>
<td>2</td>
<td>185</td>
<td>137</td>
<td>486</td>
<td>831</td>
<td>12.8</td>
<td>3.09</td>
<td>1.40</td>
<td>+++</td>
</tr>
<tr>
<td>P6</td>
<td>32</td>
<td>M</td>
<td>MANS</td>
<td>3</td>
<td>220</td>
<td>120</td>
<td>387</td>
<td>1623</td>
<td>16.6</td>
<td>1.85</td>
<td>0.83</td>
<td>++~+++</td>
</tr>
</tbody>
</table>

M, male; SBP, systolic blood pressure; DBP, diastolic blood pressure; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; MANS, malignant arteriolar nephrosclerosis; BANS, benign arteriolar nephrosclerosis; TIF, tubulointerstitial fibrosis degree; +, mild TIF; ++, moderate TIF; ++++, severe TIF.
Fig. 2. The C3aR antagonist SB290157 mitigates the C3a analogue-induced profibrotic phenotype transition and Mito FAO inhibition in HK2 cells. (A) Representative western blotting images and summarized data of C3aR and TGFβ protein levels in HK2 cells treated with PBS, DMSO, SB290157 (1 µM, 1 h) and C3a analogue (1 µg/mL, 24 h) according to the group. (B) Summarized data of relative TGFβ levels (corrected by BCA) in the medium of HK2 cells treated with PBS, DMSO, SB290157 (1 µM, 1 h) and C3a analogue (1 µg/mL, 24 h) according to the group. N = 6. (C) Representative western blotting images, summarized data of PPARα and CPT-1α protein levels of HK2 cells treated with PBS, DMSO, SB290157 (1 µM, 1 h) and C3a analogue (1 µg/mL, 24 h) according to the group. N = 6. (D) Representative immunofluorescence staining images of PPARα (200 ×, scale bar, 100 µm) and summarized data of relative mean intensity of PPARα fluorescence in HK2 cells treated with PBS, DMSO, SB290157 (1 µM, 1 h) and C3a analogue (1 µg/mL, 24 h) according to the group. N = 6. (E) Representative images of the fatty acid probe and Mito tracker (400 ×, scale bar, 50 µm) and summarized data of Mander’s coefficients in HK2 cells treated with PBS, DMSO, SB290157 (1 µM, 1 h) and C3a analogue (1 µg/mL, 24 h) according to the group. N = 3. **p > 0.05, *p < 0.05, ***p < 0.01, ****p < 0.001 by one-way ANOVA.
Fig. 3. Coincubation with recombinant rat renin increases the cleavage fragments of C3. (A) Representative western blotting images, summarized data of (B) iC3b and (C) C3c protein levels showing C3 cleavage after incubation with recombinant rat renin at 0, 1.2, 12.5 or 25 µg/mL. r-Renin, recombinant rat renin. N=3, "p > 0.05, *p < 0.05, ***p < 0.001, vs. PBS, by one-way ANOVA.

upregulated in the clipped kidneys of 2K1C rats (Fig. 5A). RT‒qPCR results also showed an increase in the mRNA levels of C3aR, α-SMA, TGFβ and macrophage marker CD68 (Fig. 5B). These results suggested that C3a/C3aR signaling was activated in the clipped kidneys of rats with renovascular hypertension.

3.6 C3aR Inhibition Restores PPARα/CPT-1α-Mediated Tubular Mito FAO to Attenuate Tubulointerstitial Fibrosis in the Clipped Kidneys of 2K1C Rats

Treatment with the C3aR antagonist SB290157 did not influence the BP of 2K1C rats at 4 weeks after surgery (Fig. 6A). The renin mRNA or C3a level in the clipped kidneys of 2K1C rats was also not influenced by SB290157 (Fig. 6B,C). Of note, tubular injury and interstitial fibrosis in the clipped kidneys of 2K1C rats were attenuated by SB290157 treatment, as indicated by reduced Scr, decreased tubular damage scores and reduced collagen deposition (Fig. 6D–H). The protein levels of C3aR, TGFβ and α-SMA were obviously increased in the clipped kidneys of 2K1C rats, while the treatment with SB290157 reduced these protein levels (Fig. 7A,B). Similar to the protein changes, the mRNA levels of C3aR, α-SMA and TGFβ were also decreased in SB290157-treated 2K1C rats compared to vehicle-treated 2K1C rats (Fig. 7C). The increased colocalization of α-SMA with CD68 in the clipped kidney cortex of 2K1C rats was mitigated by SB290157 treatment (Fig. 7D). These results revealed the ability of SB290157 to inhibit renovascular hypertension-induced tubulointerstitial fibrosis by blocking C3a/C3aR signaling.

Under TEM, a higher abundance of lipid droplets was found in the proximal TECs of the clipped kidneys of 2K1C rats. Treatment with SB290157 reduced the accumulation of lipid droplets in the proximal TECs in 2K1C rats (Fig. 8A). The protein levels of PPARα and CPT-1α were decreased significantly in the clipped kidneys of 2K1C rats (Fig. 8B). Accordingly, a noticeable decrease in the colocalization of PPARα with nuclei in TECs (marked by AQP1) was observed in the clipped kidneys of 2K1C rats (Fig. 8C). These changes were significantly alleviated by SB290157 treatment, as indicated by the restoration of PPARα and CPT-1α protein levels and the increased nuclear localization of PPARα (Fig. 8).

4. Discussion

In the clinic, renin-induced hypertension combined with tubule injury remains a problem with a high prevalence. Here, we provide new in vivo and in vitro evidence that targeting C3a/C3aR signaling may achieve some benefits in the treatment of renin-dependent hypertension-induced kidney injury. In the present study, we verified that renin cleaved C3 into C3a and activated C3a/C3aR signaling in TECs. The activation of C3a/C3aR signaling played a vital role in the tubular profibrotic phenotype transition by downregulating PPARα/CPT-1α-mediated Mito FAO. Further results proved that the C3aR antagonist SB290157 alleviated renin-dependent hypertension-induced tubulointerstitial fibrosis by restoring PPARα/CPT-1α-mediated Mito FAO and inhibiting tubular profibrotic phenotypic changes.

Few previous studies have focused on the relationship of renin with C3. Only one study has reported that human renin can cleave C3 in vitro [6]. They also reported that murine renin was unable to act on murine C3. Renin is a species-specific enzyme. In the present study, we tested the ability of renin to cleave C3 in humans and rats. Our finding that human renin could catalyze C3 cleavage in human serum is in agreement with previously reported results [6]. Notably, our results proved that recombinant rat renin could directly cleave purified rat C3. In addition, we observed that C3a levels increased synchronically with renin in the kidney cortex of clipped kidneys in 2K1C rats. Therefore, there may exist different mechanisms of renin in mice and rats. By analyzing our data and the data reported before, we
find that 1.2 µg/mL recombinant human renin could achieve significant C3 cleavage while in rat 25 µg/mL recombinant renin was required, suggesting a weaker C3 cleavage effect of rat renin.

In different disease models, the location of the C3aR protein in the kidney cortex has been reported to differ from that under normal conditions. Under normal conditions, C3aR distribution is restricted to renal epithelial cells and interstitial cells [16, 17]. However, high C3aR expression in podocytes, mesangial cells and endothelial cells has been reported in patients and animals with various chronic kidney diseases [19, 31, 32]. Here, we showed increased C3aR expression in the TECs of MANS patients with high renin activity. In comparison, C3aR expression in the TECs of
Fig. 5. C3aR and mesenchymal transition markers increase in the kidney cortex of 2K1C rats. (A) Representative western blotting images, summarized data of C3aR and α-SMA protein levels and (B) summarized C3aR, α-SMA, TGFβ and CD68 mRNA levels in the renal cortex in sham rats and 2K1C rats (clipped kidney). N = 4 per group. *p < 0.05, **p < 0.01 by independent t test.

BANS patients was much lower. These results are in line with a previous report that more complement components, including C3a, were found in MANS patients than in BANS patients and normal controls [12]. Our results provide a novel mechanism of the RAS in renal injury by activating C3a/C3aR signaling, especially in malignant hypertensive patients with a high renin state.

The location of sites with high C3aR expression indicates the potential involvement of C3a/C3aR signaling in renin-dependent hypertension-induced tubulointerstitial fibrosis. It is known that TECs adopt a profibrotic phenotype and secrete profibrotic factors, including TGFβ in the chronic kidney injury environment [33–35]. In our study, we detected an increase in TGFβ expression in HK2 cells, as well as an increase in TGFβ concentration in the culture medium, after C3a/C3aR activation. In addition, we found a significant decrease in PPARα-CPT1α-mediated tubular Mito FAO, which has been reported to occur along with TGFβ-mediated tubular interstitial fibrosis. Another study also demonstrated that defective FAO can promote TECs to secrete TGFβ and tubular profibrotic phenotype transition [36]. In addition, PPARα agonists have been reported to help reduce TGFβ expression and downstream signaling to mitigate hypertension-induced kidney injury in spontaneous hypertensive rats [37]. As the most important profibrotic cytokine, TGFβ plays a fundamental role in myofibroblast transition [38], which serves as the main mechanism of tubulointerstitial fibrosis. Infiltrating monocyte-derived macrophages are one of the important sources of myofibroblasts in the kidney interstitium [39]. The macrophage-to-myofibroblast transition can be mediated by TGFβ by canonical smad2/3 signaling and other noncanonical signaling pathways [40,41]. In the current study, similar mesenchymal transition mechanisms were observed in renin-dependent hypertension-induced kidney injury and were closely associated with renin-induced C3a/C3aR activation in TECs. Our results provide new evidence that renin-induced C3a/C3aR signaling participates in hypertension-induced tubulointerstitial fibrosis by facilitating mesenchymal transition. Taken together, these results show that C3a/C3aR activation plays a vital role in accelerating hypertension-induced kidney injury.

Another important finding in our study is that renin/C3a/C3aR activation impairs PPARα/CPT-1α-mediated tubular Mito FAO in rats suffering from hypertension. C3a/C3aR signaling has emerged as a critical regulator of cellular metabolism in recent years. One study showed that the activation of C3a/C3aR altered the metabolic phenotype of synovial fibroblasts from mitochondrial respiration to aerobic glycolysis [42]. However, no study has elucidated the detailed mechanisms how C3a/C3aR influences the downstream factor PPARα in TECs, and there are clues suggesting the potential of C3aR in regulating PPARα-mediated Mito FAO. Studies have reported that C3a/C3aR activation inhibited cAMP-PKA signaling by activating Gαi [43] to modulate mitochondrial function and energy restoration in different tissue cells [44,45]. Other studies have provided evidence that cAMP-PKA signaling plays an important role in activating PPARα [46,47]. Therefore, we speculate that cAMP-PKA signaling inhibition by C3a/C3aR may cause impaired PPARα-mediated Mito FAO in TECs. However, the detailed mechanisms still need to be further investigated.
Fig. 6. The C3aR antagonist SB290157 alleviates tubulointerstitial fibrosis in 2K1C rats. (A) Summarized blood pressure and (D) Scr levels in sham+vehicle, 2K1C+vehicle and 2K1C+SB290157 rats. N = 6 per group. (B) Summarized REN mRNA levels and (C) C3a concentration in the renal cortex in sham+vehicle, 2K1C+vehicle (clipped kidney) and 2K1C+SB290157 (clipped kidney) rats. N = 6 per group. (E) Representative H&E staining images, (F) summarized tubular damage scores, (G) representative Masson staining images and (H) summarized collagen volume fraction of the renal cortex in sham+vehicle, 2K1C+vehicle (clipped kidney) and 2K1C+SB290157 (clipped kidney) rats (200×; scale bar, 100 µm; the lower panel shows magnified images of the boxed areas in the upper panel). N = 6 per group. *p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA.
Fig. 7. The C3aR antagonist SB290157 reduces C3aR expression and mesenchymal transition in 2K1C rats. (A) Representative western blotting images and (B) summarized data of C3aR, α-SMA and TGFβ protein and (C) mRNA levels of the renal cortex in sham+vehicle, 2K1C+vehicle (clipped kidney) and 2K1C+SB290157 (clipped kidney) rats. N = 6 per group. (D) Representative immunofluorescence staining images of α-SMA and CD68 (400×; scale bar, 50 µm; white triangles, colocalization of α-SMA and CD68) and summarized data of relative CD68-positive area (%) and CD68+α-SMA+ cell counts per field in the renal cortex of sham+vehicle, 2K1C+vehicle (clipped kidney) and 2K1C+SB290157 (clipped kidney) rats. N = 3 per group, *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA.
Fig. 8. The C3aR antagonist SB290157 restores PPARα/CPT-1α-mediated tubular Mito FAO. (A) Representative TEM images of proximal TECs (8000×; scale bar, 2 µm; the lower panel shows magnified images of the boxed areas in the upper panel; yellow arrows, lipid droplet) in the renal cortex of sham+vehicle, 2K1C+vehicle (clipped kidney) and 2K1C+SB290157 (clipped kidney) rats. N = 3 per group. (B) Representative western blotting images and summarized PPARα and CPT-1α protein levels in the renal cortex of sham+vehicle, 2K1C+vehicle (clipped kidney) and 2K1C+SB290157 (clipped kidney) rats. N = 6 per group. (C) Representative immunofluorescence staining images of PPARα and DAPI (200×; scale bar, 100 µm; TECs marked by AQP1 with green fluorescence), summarized data of relative mean intensity of PPARα fluorescence and Mander’s coefficients of PPARα and DAPI in the renal cortex of sham+vehicle, 2K1C+vehicle (clipped kidney) and 2K1C+SB290157 (clipped kidney) rats. N = 3 per group. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA.
Fig. 9. Diagram showing the C3aR antagonist SB290157 targeting C3a/C3aR signaling to restore PPARα/CPT-1α-mediated Mito FAO and offset tubular profibrotic phenotype transition in renin-dependent hypertension-induced kidney injury.

C3a/C3aR signaling is widely involved in kidney diseases through various mechanisms [48]. In acute kidney injury, there is controversy about the role of C3a/C3aR signaling. Reportedly, C3a promotes the synthesis of inflammatory mediators and chemokines in ischemia–reperfusion induced kidney injury [49,50]. In Shiga toxin-associated hemolytic uremic syndrome, C3a/C3aR signaling activation induces mitochondrial dysfunction and imbalances the redox state to aggravate tubular injury [51]. However, C3a/C3aR activation in sepsis-induced kidney injury has been demonstrated to be a protective way to limit the bacterial load and renal damage [27]. In most CKD models, C3a/C3aR signaling is defined as dangerous signaling that stimulates the synthesis of proinflammatory and profibrotic cytokines in renal paracymal cells and infiltrating cells [52,53]. In addition, C3a is reported to be an important inducer of the cellular mesenchymal transition, including that of epithelial cells and endothelial cells [19,32]. Our study verifies the effect of C3a/C3aR activation in promoting tubulointerstitial fibrosis in hypertension-induced CKD. Inhibiting C3a/C3aR signaling is likely to be a potential therapeutic strategy in hypertensive subjects with tubulointerstitial fibrosis.

The C3aR antagonist SB290157 has been confirmed as a C3aR inhibitor in the lung [22], brain [54], heart [55] and kidney [31,44,56]. SB290157 treatment has proven beneficial in chronic renal fibrosis. Given the curative potential of SB290157, we performed a series of experiments to test its effect on renin-dependent hypertension-induced kidney injury. Our data are the first to demonstrate that SB290157 significantly mitigates renin-dependent hypertension-induced Mito FAO defects and tubular profibrotic phenotype transition by blocking C3a/C3aR signaling. In clinical practice, ACEIs and ARBs are frequently used to treat hypertension patients with RAS activation. However, the utilization of these drugs results in persistent renin elevation. Therefore, the blockage of C3aR may be a potent strategy for preventing tubulointerstitial injury. Of note, the inhibitor of another anaphylatoxin receptor, the C5aR inhibitor avacopan, has been approved by the FDA to treat anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis [57]. No C3aR inhibitor is currently available in the clinic. We believe that C3aR inhibitors may be a potential treatment for renin-dependent hypertension-induced kidney injury in the future.

5. Limitations

There are a few limitations of the current study. First, our study is limited by the small sample size of patients and rats employed. And we did not directly detect the C3a protein in western blotting analysis because of the lack of a C3a-specific antibody. The levels of C3a measured in tissue homogenate may underestimate the C3a concentration in clipped kidneys due to the limitations of an ELISA from tissue homogenate, as a portion of C3a may remain within the tissue matrix. We did not use the renin inhibitor aliskiren to treat 2K1C rats since its ability to inhibit renin activity in rodents has been reported to be weak [58].

Another potential limitation of our study is that we did not verify the specificity of SB290157 due to its agonistic effect on C5aR2 [59]. To prove the effect of SB290157 on C3aR, an in vitro calcium assay would be a possibility considering that SB290157 could inhibit the influx of Ca²⁺ which is increased by C3a stimulation [60,61]. But the therapeutic effect of SB290157 in vivo is hard to confirm. Despite the off-target effect of SB290157 on C5aR2, we believe that it has limited effect on our current results on account that a weak C5aR2 expression in TECs [62,63] and an insignificant effect of C5aR2 in either acute kidney injury or chronic renal fibrosis models has been reported previously [64,65].

At last, we only evaluated the role of SB290157 in 2K1C rat model to simulate renin-dependent hypertension status in vivo. For the translation of our findings to clinical applications, it is necessary to further confirm the effect of SB290157 in additional models of renin-dependent hypertension, for instance, spontaneous hypertension rats and double transgenic rats harboring both the human renin and human angiotensinogen genes (dTGR), in future studies.
6. Conclusions

The results of our study provide strong evidence that renin can cleave C3 into C3a and activate C3α/C3αR signaling in TECs to impair PPARα/CPT-1α-mediated Mito FAO both in vivo and in vitro. Treatment with SB290157 significantly mitigates renin-dependent hypertension-induced tubular profibrotic phenotype transition by blocking C3α/C3αR signaling. In summary, although in-depth studies and pilot trials are still warranted, our findings suggest that SB290157 treatment attenuates renin-dependent hypertension-induced tubulointerstitial fibrosis by restoring PPARα/CPT-1α-mediated Mito FAO and reversing the phenotypic transition of TECs through C3α/C3αR signaling (Fig. 9).

Abbreviations

ANCA, anti-neutrophil cytoplasmic antibody; AQP1, aquaporin 1; BANS, benign arteriolonephrosclerosis; BCA, bicinchoninic acid assay; BP, blood pressure; CKD, chronic kidney diseases; CPT-1α, carnitine palmitoyltransferase-1 alpha; C3αR, C3α receptor; DMEM/F12, dulbecco’s modified eagle’s medium/nutrient mixture F-12; DPBS, dulbecco’s phosphate buffered saline; E-cad, e-cadherin; FBS, fetal bovine serum; HK2, human kidney 2 cells; H&E, hematoxylin-eosin; MANS, malignant arteriolonephrosclerosis; PBS, phosphate buffered saline; PPARα, peroxisome proliferator-activated receptor alpha; PVDF, polyvinylidene difluoride; RT-qPCR, real time-quantitative polymerase chain reaction; Scr, serum creatinine; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; TECs, tubular epithelial cells; TGFβ, transforming growth factor β; α-SMA, α-smooth muscle actin; 2K1C, two-kidney one-clipped.

Availability of Data and Materials

The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.

Author Contributions

CW, ZW and WZ designed the research study. CW, ZW and KJ performed the research. TX collected the clinical data. CW, ZW and HM analyzed the data. JX and XP provided help on the analysis of histological images and transmission electron microscopy images. XF made contributions to data interpretation. XF and WZ provided supervision. CW and ZW wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors approved the final version of the paper. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

The study protocol has been approved by the Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (approval number 20220-319). Patient information was managed according to applicable data protection regulations. All participating individuals have given their written informed consent to participate in the study. Animal study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethic Committee on Animal Care of Charles River Laboratories (approval number P2021100).

Acknowledgment

We are grateful for the sacrifice of the animals in this study and thank all the participating staff of the Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University. We thank all the patients participated in the study for their cooperation.

Funding

This study was funded by the National Natural Science Foundation of China (Grant number 81470967, 81670613 and 82270705) and the Shanghai Science and Technology Committee (Grant number 21ZR1440300).

Conflict of Interest

The authors declare no conflict of interest.

References


[59] Li XX, Kumar V, Clark RJ, Lee JD, Woodruff TM. The “C3aR Antagonist” SB290157 is a Partial C5aR2 Agonist. Frontiers in Pharmacology. 2021; 11: 591398.


